Literature DB >> 23760425

[Navigated retinal laser therapy].

M Kernt1, M Ulbig, A Kampik, A S Neubauer.   

Abstract

Navigated laser therapy introduces for the first time computerized assistance systems for retinal laser therapy. The Navilas system offers high precision and safety and provides additional benefits regarding standardization of planning, execution, documentation and quality assurance. The current focus of clinical application for navigated laser therapy besides laser treatment after retinal vein occlusion and panretinal laser photocoagulation in proliferative diabetic retinopathy (PDR) is diabetic macular edema. Recent data indicate that combined initial anti-vascular endothelial growth factor (anti-VEGF) and navigated macular laser therapy allows achievement and maintenance of treatment success with a minimum number of interventions. Despite very promising results the current assessment of navigated laser therapy is still limited by the evidence available worldwide.

Entities:  

Mesh:

Year:  2013        PMID: 23760425     DOI: 10.1007/s00347-013-2868-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  27 in total

1.  [Navigated focal retinal laser therapy using the NAVILAS® system for diabetic macula edema].

Authors:  M Kernt; R Cheuteu; R G Liegl; F Seidensticker; S Cserhati; C Hirneiss; C Haritoglou; A Kampik; M Ulbig; A S Neubauer
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

Review 2.  Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process.

Authors:  Rita Ehrlich; Alon Harris; Thomas A Ciulla; Nisha Kheradiya; Diana M Winston; Barbara Wirostko
Journal:  Acta Ophthalmol       Date:  2010-03-11       Impact factor: 3.761

3.  Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS.

Authors:  Igor Kozak; Stephen F Oster; Marco A Cortes; Dennis Dowell; Kathrin Hartmann; Jae Suk Kim; William R Freeman
Journal:  Ophthalmology       Date:  2011-01-26       Impact factor: 12.079

4.  Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group.

Authors: 
Journal:  Am J Med       Date:  1991-04       Impact factor: 4.965

5.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

Authors:  Paul Mitchell; Francesco Bandello; Ursula Schmidt-Erfurth; Gabriele E Lang; Pascale Massin; Reinier O Schlingemann; Florian Sutter; Christian Simader; Gabriela Burian; Ortrud Gerstner; Andreas Weichselberger
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

6.  Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Neil M Bressler; Haijing Qin; Roy W Beck; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

Review 7.  Oxygen and diabetic eye disease.

Authors:  E Stefansson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

8.  Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy.

Authors:  E Stefansson; M B Landers; M L Wolbarsht
Journal:  Trans Am Ophthalmol Soc       Date:  1981

9.  Wide-field fundus autofluorescence corresponds to visual fields in chorioretinitis patients.

Authors:  Florian Seidensticker; Aljoscha S Neubauer; Tamer Wasfy; Carmen Stumpf; Stephan R Thurau; Anselm Kampik; Marcus Kernt
Journal:  Clin Ophthalmol       Date:  2011-11-29

10.  Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser.

Authors:  Aljoscha S Neubauer; Julian Langer; Raffael Liegl; Christos Haritoglou; Armin Wolf; Igor Kozak; Florian Seidensticker; Michael Ulbig; William R Freeman; Anselm Kampik; Marcus Kernt
Journal:  Clin Ophthalmol       Date:  2013-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.